← Back to screener

GALECTIN THERAPEUTICS INC GALT

Rank #1735 · Nasdaq · $0.2B market cap
⚠ Going-concern flag — the auditor (Cherry Bekaert LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
43.2
P/E
-4.6
P/B
-3.53
ROE
75.9%
Op. Margin
–%
Debt Ratio
-195%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -4.6x, P/B -3.53x. Ranks in the top 96% of the universe.

Profitability ★★★★★
Excellent

ROE 75.9%. Ranks in the top 5% of the universe.

Safety ★★★★★
Excellent

Debt ratio -195%. Ranks in the top 5% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$-0.0B–-40
2012–$-0.0B$-0.0B$-0.0B–-131
2013–$-0.0B$-0.0B$-0.0B–-77
2014–$-0.0B$-0.0B$-0.0B–-117
2015–$-0.0B$-0.0B$0.0B–146
2016–$-0.0B$-0.0B$0.0B–6
2017–$-0.0B$-0.0B$0.0B–21
2018–$-0.0B$-0.0B$0.0B–29
2019–$-0.0B$-0.0B$-0.0B–-398
2020–$-0.0B$-0.0B$0.0B–55
2021–$-0.0B$-0.0B$0.0B–12
2022–$-0.0B$-0.0B$0.0B–175
2023–$-0.0B$-0.0B$0.0B–5989
2024–$-0.0B$-0.0B$-0.0B–-261
2025–$-0.0B$-0.0B$-0.1B–-195

← See the full screener